ERBB2 and cervical carcinoma: In addition, a recent study demonstrated a promising effect of lapatinib (anti- EGFR and HER-2), in HER-expressing cervical cancer cells by reducing the number and size of blood vessels and preventing increased HIF-1α levels28.